Use of dithiocarbamates to treat myelosuppression

Details Use of dithiocarbamates to treat myelosuppression Use of dithiocarbamates to treat myelosuppression

1992-07-30

1994-03-15

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Identification or warning feature

Taste or smell or chemical irritation to the eye, nose, or...

514476, A61K 3900, A61K 3127

Patent

active

052944301

ABSTRACT:
A process for preventing or ameliorating the myelosuppression which can occur in a mammal such as a human cancer patient being treated with a platinum-free antineoplastic drug is provided, comprising administering an effective dosage of a dithiocarbamate compound to said mammal, preferably subsequent to administration of the cytotoxic drug.

REFERENCES:
patent: 4053587 (1977-10-01), Davidson et al.
patent: 4137248 (1979-01-01), Gale et al.
patent: 4148885 (1979-04-01), Renoux et al.
patent: 4426372 (1984-01-01), Borch
patent: 4529543 (1982-07-01), Renoux et al.
patent: 4562275 (1985-12-01), Speer et al.
patent: 4581224 (1986-04-01), Borch
patent: 4594238 (1986-06-01), Borch
patent: 4645661 (1987-02-01), Schonbaum et al.
patent: 4680308 (1987-07-01), Schwartz et al.
patent: 4721096 (1988-01-01), Naughton et al.
patent: 5035878 (1991-07-01), Borch
Innes et al. J. National Cancer Institute 42:1101-1114 (1969).
Prasad et al. Cell & Chromosome Res. 6(3):82-84 (1983).
B. Rosenberg, Cancer Treatment Reports 63: 1433-1438 (1979).
G. D. Thorn et al The Dithiocarbamates and Related Compounds, (Chapter 2, pp. 7-42) Elsevier, New York (1962).
J. S. Greenberger, in Hematopoiesis, pp. 203-242, D. W. Golde (ed.) Churchill Livingstone, Edinburgh (1984).
T. K. Schmalbach et al., Cancer Res. 49: 2574-2577 (1989).
R. Qazi et al., J. Natl. Cancer Inst. 80: 1486-1488 (1988).
L. H. Williams et al., Exp. Hematol. 16: 80-87 (1988).
D. A. Juckett et al., AACR Abstracts 25: 322 (Abstract No. 1274) (1984).
D. L. Bodenner et al., Cancer Res. 46: 2751-2755 (1986).
R. G. Evans et al., Cancer Res. 44: 3686-3690 (1984).
J. D. Khandekar, Res. Communications Chem. Path. and Pharmacol. 40: 55-66 (1983).
A. Gringeri et al., AACR Abstracts, p. 371, Abstract No. 1471 (1984).
I. M. Pannacciulli et al., Br. J. Cancer 59: 371 (1989).
H. Prasad et al., Cell and Chromosome Res. 6: 82-84 (1983).
J. R. M. Innes et al., J. National Cancer Institute 42: 1101-1114 (1969).
R. C. Gamelli et al., Cancer Chemother. Pharmacol. 16: 153-155 (1986).
F. W. Sunderman, Sr., Annals Clinical Res. 3: 182-185 (1971).
M. M. Jones et al., Cancer Chemother. Pharmacol. 17: 38-42 (1986).
A. Gringeri et al., Cancer Research 48: 5708-5712 (1988).
R. I. Freshey, Culture of Animal Cells, A Manual of Basic Technique (2nd ed.), pp. 284-288, Alan R. Liss, Inc. (1987).
M. Y. Gordon et al., Internatl. J. Cell Cloning 1: 429-439 (1983).
Allalunis-Turner et al., Int. J. Radiat. Oncol. Biol. Phys. 10: 1569-1573.
Remington's Pharmaceutical Sciences, A. Osol, ed., Mack Publishing Co. (16th ed. 1980) at pp. 1083-1085, 1090-1091.
Sigma Chemical Co., 1381 (1989).
K. Ikebochi et al., PNAS USA, 84, 9035 (1987).
The Merck Index (11th ed.), p. 610, S. Budavani (ed.), Merck & Co., Inc., Rahway, N.J. (1989).
The Physicians Desk Reference (41st ed.), pp. 768-769, E. R. Barnhart (publ.), Medical Economics Co., Oradell, N.J. (1987).
T. Schamlbach et al., Blood, 76 (10 Suppl. 1) 164a (1990).

Affiliated with

Also associated with

Rating

Use of dithiocarbamates to treat myelosuppression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of dithiocarbamates to treat myelosuppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dithiocarbamates to treat myelosuppression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1534634